Tepetam, Fatma MerveColakoglu, BahattinOzer, FarukMaden, EminYosunkaya, SebnemDuman, Dildar2020-03-262020-03-2620141305-2381https://hdl.handle.net/20.500.12395/31250Objective: Analgesic and anti-inflammatory treatment in patients with a positive history of ASA (acetyl salicylic acid) /NSAID (non-steroidal anti-inflammatory drugs) intolerance is a significant problem in clinical practice. Therefore, there is a need to identify an alternative drug that is safe and reliable. Our aim was to determine the safety of nimesulide, a preferential COX-2 inhibitor. Material and Method: A single blind, placebo-controlled oral challenge procedure was applied to 95 patients (37 male, 58 female; with a mean age of 40.19 +/- 13.94 years) who had suffered from adverse reactions to ASA/NSAIDs. Results: According to patient histories, the majority of intolerance reactions were due to NSAIDs, and isolated cutaneous symptoms were the most common presenting symptom in 43 subjects (45.2%). While isolated respiratory symptoms were experienced in only 6 (6.3%) patients. Nimesulide was well tolerated in 90 out of 95 patients (95.2%) and only 5 of the 95 patients (4.8%) presented an adverse reaction, which was a slight urticaria. Two of the five patients were suffering from chronic urticaria, one patient had asthma and rhinosinusitis, one was atopic and one had a history of allergic reaction to a beta-lactam. Conclusion: Nimesulide can be a good option for NSAID-intolerant patients: it should first be tested in an allergy unit. However, the results of the current study need further clinical studies to evaluate the effects of higher doses or the prolonged use of nimesulide and whether nimesulide could be used in patients with asthma and with a history of chronic urticaria.eninfo:eu-repo/semantics/closedAccessAspirindrug allergynimesulideArticle1038187Q4WOS:000346628200015Q4